和径医药科技

HGT Molecular Medicine is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company leverages its deep expertise in medicinal chemistry and biology to target validated pathways such as glucokinase activation and hormone receptor modulation. Its lead programs include treatments for Type 2 diabetes and various endocrine-related cancers. HGT Molecular Medicine aims to address significant unmet medical needs in the Chinese and global markets through a combination of internal R&D and strategic collaborations.